Programmes and principles in treatment of multidrug-resistant tuberculosis
- PMID: 14962530
- DOI: 10.1016/S0140-6736(04)15496-2
Programmes and principles in treatment of multidrug-resistant tuberculosis
Abstract
Multidrug-resistant tuberculosis (MDR-TB) presents an increasing threat to global tuberculosis control. Many crucial management issues in MDR-TB treatment remain unanswered. We reviewed the existing scientific research on MDR-TB treatment, which consists entirely of retrospective cohort studies. Although direct comparisons of these studies are impossible, some insights can be gained: MDR-TB can and should be addressed therapeutically in resource-poor settings; starting of treatment early is crucial; aggressive treatment regimens and high-end dosing are recommended given the lower potency of second-line antituberculosis drugs; and strategies to improve treatment adherence, such as directly observed therapy, should be used. Opportunities to treat MDR-TB in developing countries are now possible through the Global Fund to Fight AIDS, TB, and Malaria, and the Green Light Committee for Access to Second-line Anti-tuberculosis Drugs. As treatment of MDR-TB becomes increasingly available in resource-poor areas, where it is needed most, further clinical and operational research is urgently needed to guide clinicians in the management of this disease.
Comment in
-
Treatment of multidrug-resistant tuberculosis.Lancet. 2004 Apr 10;363(9416):1240. doi: 10.1016/S0140-6736(04)15970-9. Lancet. 2004. PMID: 15081672 No abstract available.
Similar articles
-
Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment.Br Med Bull. 2005 Jun 14;73-74:17-24. doi: 10.1093/bmb/ldh047. Print 2005. Br Med Bull. 2005. PMID: 15956357 Review.
-
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.J Assoc Physicians India. 2006 Mar;54:219-34. J Assoc Physicians India. 2006. PMID: 16800350
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
[Multidrug resistant tuberculosis in Romania in the last years (2004-2007)--an extremely important social phenomenon].Pneumologia. 2008 Oct-Dec;57(4):195-200. Pneumologia. 2008. PMID: 19186681 Romanian.
-
Development of a standardised multidrug-resistant/extensively drug-resistant tuberculosis assessment and monitoring tool.Int J Tuberc Lung Dis. 2009 Oct;13(10):1305-8. Int J Tuberc Lung Dis. 2009. PMID: 19793438
Cited by
-
GenoMycAnalyzer: a web-based tool for species and drug resistance prediction for Mycobacterium genomes.BMC Genomics. 2024 Apr 20;25(1):387. doi: 10.1186/s12864-024-10320-3. BMC Genomics. 2024. PMID: 38643090 Free PMC article.
-
Active tuberculosis of spine: Current updates.N Am Spine Soc J. 2023 Aug 21;16:100267. doi: 10.1016/j.xnsj.2023.100267. eCollection 2023 Dec. N Am Spine Soc J. 2023. PMID: 37736557 Free PMC article.
-
Depression Among Patients With Tuberculosis at a Directly Observed Treatment Short-Course (DOTS) Center in Rural Delhi.Cureus. 2022 Oct 29;14(10):e30827. doi: 10.7759/cureus.30827. eCollection 2022 Oct. Cureus. 2022. PMID: 36457614 Free PMC article.
-
Assessment of Adverse Drug Events, Their Risk Factors, and Management Among Patients Treated for Multidrug-Resistant TB: A Prospective Cohort Study From Pakistan.Front Pharmacol. 2022 May 17;13:876955. doi: 10.3389/fphar.2022.876955. eCollection 2022. Front Pharmacol. 2022. PMID: 35656303 Free PMC article.
-
A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments.Front Pharmacol. 2021 Dec 13;12:736986. doi: 10.3389/fphar.2021.736986. eCollection 2021. Front Pharmacol. 2021. PMID: 34966276 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
